Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or acquired s
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
03:37pm, Friday, 10'th Apr 2026
LOS ANGELES, April 10, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Atara Biot
New York, New York--(Newsfile Corp. - April 10, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between M
Portnoy Law Firm Announces Class Action on Behalf of Atara Biotherapeutics, Inc. Investors
02:27pm, Friday, 10'th Apr 2026
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Atara Biotherapeutics, Inc., (“Atara” or the "Company") (NASDAQ: ATRA) investors of a class action on behalf of invest
NEW YORK, April 10, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA).
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
10:22am, Friday, 10'th Apr 2026
LOS ANGELES, April 10, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Atara Biotherapeutics, Inc. (�
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or acquired s
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between May 20, 202
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
10:00am, Thursday, 09'th Apr 2026
NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) and certain of
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
12:08pm, Wednesday, 08'th Apr 2026
LOS ANGELES, April 08, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Atara To Contact Him Directly To Discuss Their Options If you purchased or acquired s
New York, New York--(Newsfile Corp. - April 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Atara Biotherapeutics, Inc. (NASDAQ: ATRA) between Ma
ATRA INVESTOR REMINDER: Atara Biotherapeutics, Inc. Investors Have Until May 22, 2026 To Seek Lead Plaintiff Role
06:00pm, Tuesday, 07'th Apr 2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ:ATRA) investment, contact Lauren Molinaro of Ki
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers – ATRA
03:42pm, Tuesday, 07'th Apr 2026
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Atara Biotherapeutics, Inc. (“Atara” or the “Company”) (NASDAQ: ATRA) an
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 07'th Apr 2026
LOS ANGELES, April 7, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA) have
